ABCL FCF Margin
Free cash flow as a percentage of revenue, showing how much of each sales dollar becomes cash.
FCF Margin
Latest: 587.4% (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | -484.3% |
| 2023Q2 | -72.6% |
| 2023Q3 | -309.7% |
| 2023Q4 | -370.9% |
| 2024Q1 | -661.5% |
| 2024Q2 | -683.8% |
| 2024Q3 | -728.4% |
| 2024Q4 | -467.9% |
| 2025Q1 | -524.0% |
| 2025Q2 | -267.9% |
| 2025Q3 | -687.0% |
| 2025Q4 | -99.4% |
| 2026Q1 | -449.2% |
| 2026Q2 | 587.4% |
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 6
Revenue
EPS
Free Cash Flow
Cumulative FCF
Shares Outstanding
Total Assets
Healthcare Comparison
1 / 3
Latest FCF Margin: 587.4% (2026Q2); +855.3 pp YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, FCF Margin ranged from -728.4% in 2024Q3 to 587.4% in 2026Q2.